Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13944213 | 0.99 | HTT (0.45) | HTTL3MBTL1MAPTTGM2KEAP1 | |
| SCHEMBL3820665 | 0.87 | HTT (0.43) | HTTL3MBTL1MAPTTGM2KEAP1 | |
| SCHEMBL15927264 | 0.83 | HTT (0.49) | HTTL3MBTL1MAPTTGM2KEAP1 | |
| SCHEMBL917788 | 0.82 | HTT (0.65) | HTTL3MBTL1TGM2KEAP1NFE2L2 | |
| SCHEMBL5562255 | 0.81 | HTT (0.56) | HTTL3MBTL1MAPTTGM2KEAP1 | |
| SCHEMBL917878 | 0.80 | HTT (0.67) | HTTL3MBTL1MAPTTGM2KEAP1 | |
| SCHEMBL1852073 | 0.80 | SMN1; SMN2 (0.51) | HTTL3MBTL1MAPTKMT2ALMNA | |
| SCHEMBL13871818 | 0.80 | MAPT (0.55) | L3MBTL1MAPTMGLL | |
| SCHEMBL918470 | 0.79 | HTT (0.65) | HTTL3MBTL1TGM2KEAP1NFE2L2 | |
| SCHEMBL23652155 | 0.79 | MAPT (0.41) | HTTL3MBTL1MAPTTGM2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2024-02-29 | — | — | US | disclosed |
| EP-3851447-B1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC (CA) | 2023-09-06 | — | — | EP | disclosed |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2021-12-16 | — | — | US | disclosed |
| EP-2862581-B1 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LP (CA) | 2021-08-11 | — | — | EP | disclosed |
| EP-3851447-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI Limited Partnership (CA) | 2021-07-21 | — | — | EP | disclosed |
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BELLUS HEALTH INC. (CA) | 2021-06-01 | — | — | US | disclosed |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | Bellus Health, Inc. (CA) | 2020-12-08 | — | — | US | disclosed |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2020-08-13 | — | — | US | disclosed |
| US-10238611-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BELLUS HEALTH INC. (CA) | 2019-03-26 | — | — | US | disclosed |
| US-20170095430-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH INC. (CA) | 2017-04-06 | — | — | US | disclosed |
| US-9499480-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2016-11-22 | — | — | US | disclosed |
| EP-2862581-A2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI Limited Partnership (CA) | 2015-04-22 | — | — | EP | disclosed |
| EP-2089417-B1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI LTD PARTNERSHIP (CA) | 2014-12-31 | — | — | EP | disclosed |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BHI LIMITED PARTNERSHIP (CA) | 2014-08-07 | — | — | US | disclosed |
| US-8748656-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | BHI LIMITED PARTNERSHIP (CA) | 2014-06-10 | — | — | US | disclosed |
| EP-2089417-A2 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS Health (International) Limited (CH) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009019534-A2 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | BELLUS HEALTH (INTERNATIONAL) LIMITED (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | BELLUS HEALTH INC. (CA) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170095430-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | HTT 19/4885L3MBTL1 2844/4885MAPT 24/4885 |
| US-20240065990-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | HTT 19/4885L3MBTL1 2822/4885MAPT 22/4885 |
| US-11020360-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | HTT 19/4885L3MBTL1 2821/4885MAPT 31/4885 |
| US-10857109-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | HTT 19/4885L3MBTL1 2821/4885MAPT 31/4885 |
| US-20210386693-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | HTT 19/4885L3MBTL1 2844/4885MAPT 24/4885 |
| US-20200253897-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | HTT 19/4885L3MBTL1 2844/4885MAPT 24/4885 |
| US-20080146642-A1 | Propanesulfonic acid amino acid prodrugs that can deliver 3-amino-1-propanesulfonic acid (3APS) by minimizing metabolism associated with that drug, particularly compounds that block or protect amino group of 3APS such that it avoids metabolism by transaminases or monoamine oxidase; Alzheimer's disease | DNPEP, DAO, APP | HTT 349/4885L3MBTL1 1937/4885MAPT 198/4885 |
| US-20140220122-A1 | METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID | APP, PSEN1, PSEN2 | HTT 19/4885L3MBTL1 2844/4885MAPT 24/4885 |
| US-10238611-B2 | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid | APP, PSEN1, DNPEP | HTT 19/4885L3MBTL1 2821/4885MAPT 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.